Literature DB >> 29206780

Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?

Sandip Basu1,2, Rahul V Parghane1,2, Vikas Ostwal3,2, Shailesh V Shrikhande4,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29206780     DOI： 10.1097/MNM.0000000000000776

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


× No keyword cloud information.
  1 in total

1.  Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?

Authors:  Sandip Basu; Rahul V Parghane; Sharmila Banerjee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-18       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.